MDM2 and neuroblastoma: These observations thereby demonstrate the necessity of MYCN to overcome p53-mediated tumor suppression during neuroblastoma tumorigenesis either via direct inhibition of p53 by MDM2 or suppression of the p14ARF/p53 pathway (Chen et al., 2009).